Median Technologies announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its eyonis® LCS device. This technology uses artificial intelligence to assist in the detection and diagnosis of lung cancer during screening.
The eyonis® LCS system is designed to improve the accuracy and efficiency of lung cancer screening by analyzing medical imaging data. The clearance marks a significant step in integrating AI tools into clinical workflows for early lung cancer detection.
**Why this matters**
Lung cancer remains a leading cause of cancer-related deaths worldwide, and early detection is critical for improving patient outcomes. The FDA clearance of an AI-based device like eyonis® LCS represents progress in leveraging advanced technology to enhance screening processes, potentially leading to earlier diagnosis and more effective treatment.
Source: NewsData